Status
Conditions
Treatments
About
A post-market study of the QuickClear Mechanical Thrombectomy system used for the removal of acute Deep Vein Thrombosis (DVT) from the deep veins of legs in the setting of an office interventional suite.
Full description
The QuickClear Mechanical Thrombectomy system will be used in accordance with the Instruction for Use (IFU) to remove acute, symptomatic occlusive common femoral, external iliac or common iliac DVT or occlusive above and below knee popliteal DVT in an office based interventional suite. The intent of this post-market observational study is to further assess long-term safety and effectiveness of patients treated with the QuickClear Mechanical Thrombectomy system and to assess the feasibility of performing deep vein thrombectomy procedures in the office interventional suite.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or Non-Pregnant Female, age 18 to 89.
For females of reproductive potential: negative pregnancy test ≤ 7 days before the procedure, use of highly effective contraception (abstinence is acceptable) for 12 months after the study treatment.
Onset of acute DVT symptoms of 14 days or less in the target limb.
Ability to take oral medication and be willing to adhere to the prescribed anti- coagulant regiment.
Occlusive DVT (confirmed by either venous duplex ultrasound or CT venogram) spanning at least one of the following:
People who have scheduled or will be scheduled for treatment with the QuickClear Mechanical Thrombectomy system
Symptomatic DVT defined as meeting at least one of the following clinical indicators:
Exclusion criteria
Loading...
Central trial contact
Elizabeth Gagne, PhD; Maria Myslinski, RN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal